Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.
De Divitiis C, von Arx C, Grimaldi AM, Cicala D, Tatangelo F, Arcella A, Romano GM, Simeone E, Iaffaioli RV, Ascierto PA, Tafuto S; European Neuroendocrine Tumor Society (ENETS) Center of Excellence-Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy).
De Divitiis C, et al. Among authors: cicala d.
J Transl Med. 2016 May 3;14(1):113. doi: 10.1186/s12967-016-0857-1.
J Transl Med. 2016.
PMID: 27142424
Free PMC article.